000			02088 a2200589 4500
005			20250515045957.0
264		0	_c20071101
008			200711s 0 0 eng d
022			_a1470-269X
024	7		_a10.1038/sj.tpj.6500426 _2doi
040			_aNLM _beng _cNLM
100	1		_aBadenhorst, D
245	0	0	_aImpact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy. _h[electronic resource]
260			_bThe pharmacogenomics journal _cOct 2007
300			_a339-45 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use
650	0	4	_aCardiomyopathy, Dilated _xdrug therapy
650	0	4	_aCardiotonic Agents _xtherapeutic use
650	0	4	_aCardiovascular Agents _xpharmacology
650	0	4	_aCase-Control Studies
650	0	4	_aDigoxin _xtherapeutic use
650	0	4	_aDiuretics _xtherapeutic use
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aFurosemide _xtherapeutic use
650	0	4	_aGene Frequency
650	0	4	_aGenetic Predisposition to Disease
650	0	4	_aHaplotypes
650	0	4	_aHeart Ventricles _xpathology
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPolymorphism, Restriction Fragment Length
650	0	4	_aProspective Studies
650	0	4	_aReceptors, Adrenergic, beta-2 _xgenetics
650	0	4	_aRisk Factors
650	0	4	_aStroke Volume _xdrug effects
650	0	4	_aSystole
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aVentricular Function, Left _xdrug effects
650	0	4	_aVentricular Remodeling _xdrug effects
700	1		_aNorton, G R
700	1		_aSliwa, K
700	1		_aBrooksbank, R
700	1		_aEssop, R
700	1		_aSareli, P
700	1		_aWoodiwiss, A J
773	0		_tThe pharmacogenomics journal _gvol. 7 _gno. 5 _gp. 339-45
856	4	0	_uhttps://doi.org/10.1038/sj.tpj.6500426 _zAvailable from publisher's website
999			_c16688785 _d16688785